Galera Therapeutics, Inc. (GRTX)

NASDAQ: GRTX · IEX Real-Time Price · USD
1.72
+0.02 (1.18%)
At close: Dec 2, 2022 3:28 PM
1.71
-0.01 (-0.58%)
After-hours: Dec 2, 2022 4:00 PM EST
1.18%
Market Cap 48.45M
Revenue (ttm) n/a
Net Income (ttm) -62.84M
Shares Out 26.82M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 119,429
Open 1.69
Previous Close 1.7
Day's Range 1.67 - 1.74
52-Week Range 1.12 - 5.39
Beta 1.44
Analysts Buy
Price Target 11.48 (+583.3%)
Earnings Date Nov 9, 2022

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patient... [Read more]

Industry Biotechnology
IPO Date Nov 7, 2019
Employees 30
Stock Exchange NASDAQ
Ticker Symbol GRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for GRTX stock is "Buy." The 12-month stock price forecast is 11.48, which is an increase of 583.33% from the latest price.

Price Target
$11.48
(583.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Galera to Present at Piper Sandler Annual Healthcare Conference

MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

1 week ago - GlobeNewsWire

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

3 weeks ago - GlobeNewsWire

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncolo...

Tumor outcomes and overall survival maintained in patients with HNC at one-year

1 month ago - GlobeNewsWire

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

2 months ago - GlobeNewsWire

Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

2 months ago - GlobeNewsWire

Galera Appoints Eugene P. Kennedy, M.D.

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

3 months ago - GlobeNewsWire

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

3 months ago - GlobeNewsWire

Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation

Galera Therapeutics Inc (NASDAQ: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non-smal...

5 months ago - Benzinga

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated

5 months ago - GlobeNewsWire

Galera to Present at Jefferies Healthcare Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

6 months ago - GlobeNewsWire

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Resu...

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy

6 months ago - GlobeNewsWire

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022

6 months ago - GlobeNewsWire

Galera Announces Plan to Submit Avasopasem NDA by Year End

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022 After discussions with FDA, Company is on tra...

6 months ago - GlobeNewsWire

Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis

Galera Therapeutics Inc (NASDAQ: GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemo...

7 months ago - Benzinga

Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

7 months ago - GlobeNewsWire

Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission

8 months ago - GlobeNewsWire

Galera to Present at H.C. Wainwright BioConnect Conference

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

10 months ago - GlobeNewsWire

Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20

Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating.  Analyst Yigal Nochomovitz is re-introducing avasopasem wi...

11 months ago - Benzinga

Are Options Traders Betting on a Big Move in Galera (GRTX) Stock?

Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today

Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Galera...

11 months ago - InvestorPlace

Why Galera Shares Are Surging More Than Double Today?

Galera Therapeutics Inc (NASDAQ: GRTX) has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis (SOM) in patients with locally advanced head and ne...

11 months ago - Benzinga

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Tr...

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)

11 months ago - GlobeNewsWire

Galera to Present at Two Upcoming Investor Conferences in November

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

1 year ago - GlobeNewsWire

Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis

1 year ago - GlobeNewsWire

Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galera Therapeutics, Inc. (GRTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

1 year ago - Zacks Investment Research